Good morning, you're listening to Markets Desk.
Lululemon's turnaround story just got a new chapter, and it's a complicated one. Heidi O'Neill steps in as CEO inheriting a North American business that's been losing ground, with customer loyalty fraying and the brand's cultural cachet dimming. The challenge is familiar — she faced a similar inflection point at Nike before departing, which raises real questions about execution this time around.
Shifting to fintech, Block has filed with the Office of the Comptroller of the Currency to establish Builders Bank and Trust, a national trust charter designed to bring Cash App and Square under a unified compliance umbrella. The strategic logic is straightforward — cutting out costly sponsor-bank relationships and internalizing regulatory infrastructure could meaningfully improve margins as the company scales both payments rails.
And in pharma, Millennium Management's Israel Englander more than doubled his fund's position in AbbVie while initiating a stake in SpaceX. AbbVie's diversified pipeline beyond Humira appears to be the draw, while the SpaceX move signals continued institutional appetite for late-stage private exposure ahead of any potential liquidity event. Both positions reflect a deliberate tilt toward durable cash-flow assets and long-duration growth bets simultaneously.
That's the tape. Markets Desk, signing off the floor.
